Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC134
- Development stage
- Unknown
- Lead developer
- Scancell
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SC134 is a humanized monoclonal antibody developed by Scancell using its GlyMab platform, specifically targeting the glycolipid fucosyl-GM1 (FucGM1). FucGM1 is highly expressed in small cell lung cancer (SCLC) but is virtually absent in normal tissues, making it an ideal target for directed therapy. While originally a murine IgG1, SC134 has been humanized and developed as a T-cell engaging bispecific antibody (SC134-TCB) to redirect T-cell cytotoxicity against SCLC cells. Preclinical studies have also demonstrated its efficacy as an antibody-drug conjugate (ADC). As of early 2026, the program is transitioning into Phase 1/2 clinical trials following regulatory advice from the FDA and MHRA.
- Other names
- SC134-Scancell-antibodySC-134-Scancell-antibodySC 134-Scancell-antibody
02
Targets
Fuc-GM1 (Fucosyl-GM1 ganglioside)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on SC134.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC134.